Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Heitz

Showing results (101-110 of 178) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice VariantPauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
Gynecologic Oncology|January 8, 2016
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 studyPhilipp Harter, Toby Johnson, Dominique Berton-Rigaud, et al.
Gynecologic Oncology|August 28, 2024
Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS studyLenka Fricová, Stefan Kommoss, Giovanni Scambia, et al.
Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
Cancer Causes & Control : CCC|January 5, 2017
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association ConsortiumAna Babic, Daniel W Cramer, Linda E Kelemen, et al.
Oncogene|November 9, 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trialCeline Callens, Manuel Rodrigues, Adrien Briaux, et al.
Gynecologic Oncology|February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trialBhavana Pothuri, Sileny Han, Dana M Chase, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 19, 2023
The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial designMelisa Guelhan Inci, Jalid Sehouli, Eva Schnura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian CancerFlorian Heitz, Stefan Kommoss, Roshan Tourani, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trialAntonio González-Martín, Christophe Desauw, Florian Heitz, et al.
Pageof 18

Showing results (101-110 of 178) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice VariantPauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, et al.
Gynecologic Oncology|January 8, 2016
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 studyPhilipp Harter, Toby Johnson, Dominique Berton-Rigaud, et al.
Gynecologic Oncology|August 28, 2024
Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS studyLenka Fricová, Stefan Kommoss, Giovanni Scambia, et al.
Gynecologic Oncology|June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trialGiorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
Cancer Causes & Control : CCC|January 5, 2017
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association ConsortiumAna Babic, Daniel W Cramer, Linda E Kelemen, et al.
Oncogene|November 9, 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trialCeline Callens, Manuel Rodrigues, Adrien Briaux, et al.
Gynecologic Oncology|February 7, 2024
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trialBhavana Pothuri, Sileny Han, Dana M Chase, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 19, 2023
The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial designMelisa Guelhan Inci, Jalid Sehouli, Eva Schnura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian CancerFlorian Heitz, Stefan Kommoss, Roshan Tourani, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trialAntonio González-Martín, Christophe Desauw, Florian Heitz, et al.
Pageof 18